J&J | Jotup

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on:

Tuesday, January 16, 2024

Brodsky, Harpoon, ADS, Johnson & Johnson, AstraZeneca, BSX, JNJ, J&J, Boston Scientific, AZN, MRK, Security (finance)

BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points:

BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on:

Monday, January 8, 2024

ADS, Harpoon, Johnson & Johnson, Brodsky, AstraZeneca, J&J, Boston Scientific, JNJ, AZN, MRK, BSX, Security (finance)

BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points:

BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Sofinnova Partners Brings in Dr. Joshua Makower, Stanford Biodesign Co-Founder, as Venture Partner

Retrieved on:

Thursday, January 4, 2024

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Dr. Joshua Makower, co-founder and director of the Stanford Byers Center for Biodesign , has joined Sofinnova as an advisory Venture Partner.

Key Points:

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Dr. Joshua Makower, co-founder and director of the Stanford Byers Center for Biodesign , has joined Sofinnova as an advisory Venture Partner.
He is the Founder & Executive Chairman of ExploraMed, a medical device incubator that has created eleven companies since 1995.
Dr. Makower was a longtime partner in NEA’s healthcare practice, advising the healthcare team and medtech/healthtech investing practice.
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: “We are incredibly fortunate to have Josh on board.

J&J Bagging Announces Strategic Investment by CGB Enterprises, Inc.

Retrieved on:

Friday, December 29, 2023

J&J, Growth, Transport, Partnership, Grain, CGB, Senior

This collaboration is set to empower J&J Bagging to continue its impressive trajectory in the agribusiness sector.

Key Points:

This collaboration is set to empower J&J Bagging to continue its impressive trajectory in the agribusiness sector.
By leveraging CGB's extensive resources and expertise, J&J Bagging will further improve its business model, with a focus on delivering high-quality products and services in feed, seed, and fertilizer markets.
The investment marks a new chapter for both companies, promising enhanced growth and innovation.
Joseph Mohamed, President of J&J Bagging, expressed enthusiasm about the new partnership, stating, "This strategic investment from CGB is a game-changer for us.

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Retrieved on:

Thursday, December 21, 2023

Technology transfer, Johnson & Johnson, J&J, Janssen Pharmaceuticals, DSM-IV codes, Commercial property

LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced an asset purchase agreement with Janssen Pharmaceuticals, Inc. (J&J), a Johnson & Johnson company, for the remaining interests in bota-vec for the treatment of XLRP, as well as a commercial supply agreement and a technology transfer agreement for bota-vec manufacturing.

Key Points:

MeiraGTx to receive $130 million in upfront and near-term milestone payments, including $65 million at signing, an additional $50 million anticipated in the first quarter of 2024, with the remaining $15 million in milestone payments expected later in 2024.
The Company will receive up to an additional $285 million in cash payments upon first commercial sales of bota-vec in the U.S. and EU and for manufacturing technology transfer.
MeiraGTx has also entered into a commercial supply agreement with J&J for bota-vec manufacturing.
is serving as financial advisor and Morgan Lewis & Bockius LLP is serving as legal advisor to MeiraGTx.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on:

Monday, December 4, 2023

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points:

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on:

Tuesday, November 21, 2023

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points:

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic

Retrieved on:

Wednesday, December 13, 2023

Recent media reports indicate that J&J has abandoned litigation to settle cases with law firms representing approximately 100 victims of mesothelioma who were exposed to talc.

Key Points:

Recent media reports indicate that J&J has abandoned litigation to settle cases with law firms representing approximately 100 victims of mesothelioma who were exposed to talc.
The science is clear.”
Scientific consensus is unequivocal that asbestos exposure from J&J's products causes both mesothelioma and ovarian cancer.
J&J's prior failed bankruptcy strategy, attorneys say, not only harmed cancer victims and their families but also adversely impacted shareholders.
Concludes Mr. Birchfield, “The law says that bankruptcy can’t be used as a tactic in litigation to wear down plaintiffs and drive down the value of claims.

Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won’t Resolve Victims’ Talc Claims’ by Andy Birchfield

Retrieved on:

Tuesday, December 5, 2023

Communications, Legal, Professional Services, Publishing, Asbestos, JNJ, NYSE, Johnson & Johnson, History, Mesothelioma, Weapon, Ovarian cancer, Talc, Bankruptcy, Face, J&J, Pharmaceutical industry, Bloomberg Law

Dozens of peer-reviewed scientific studies have reinforced the connection between talc usage and these debilitating diseases, with the presence in talc of asbestos, a known carcinogen, raising alarming concerns.

Key Points:

Dozens of peer-reviewed scientific studies have reinforced the connection between talc usage and these debilitating diseases, with the presence in talc of asbestos, a known carcinogen, raising alarming concerns.
Rather than acknowledging the scientific evidence and providing equitable compensation to victims, Birchfield argues that Johnson & Johnson has resorted to evasive tactics and legal maneuvering.
Birchfield also sheds light on J&J's unwillingness to negotiate in good faith if it retains the threat of bankruptcy, which previously halted jury trials.
In light of J&J signaling a third bankruptcy filing, Birchfield calls for a united front to refuse further negotiations within the bankruptcy arena.

Talc Lawyer: Johnson & Johnson Settlements Undermine Bankruptcy Strategy, Serve as Acknowledgment That Baby Powder Contained Asbestos

Retrieved on:

Friday, November 17, 2023

Legal, Professional Services, Woman, Asbestos, Baby powder, JNJ, NYSE, Johnson & Johnson, Alameda County Superior Court, Patient, Mesothelioma, FDA, Ovarian cancer, Talc, Action Replay, Bankruptcy, Superior court, J&J, Pharmaceutical industry

Andy Birchfield , head of the Mass Torts Section at the Beasley Allen Law Firm, says the settlements have profound implications.

Key Points:

Andy Birchfield , head of the Mass Torts Section at the Beasley Allen Law Firm, says the settlements have profound implications.
“Perhaps this is an indication that J&J is abandoning its ‘bankruptcy or bust’ strategy in favor of good faith settlement discussions.
In October 2019, an FDA lab analysis of a Johnson’s Baby Powder sample revealed asbestos in the talc, leading to a voluntary recall of 33,000 bottles of Baby Powder.
We remain steadfast in our commitment to representing the interests of ovarian cancer patients and pursuing fair resolutions in the ongoing litigation against Johnson & Johnson.”